Acrux Limited ( (AU:ACR) ) has shared an announcement.
Acrux Limited has announced the issuance of 571,428 fully paid ordinary shares to its directors, following approval at an Extraordinary General Meeting. These shares are part of a larger Share Placement and Share Purchase Plan, and were issued without disclosure to investors under specific sections of the Corporations Act. This move reflects the company’s ongoing strategic efforts to strengthen its financial positioning and engage stakeholders in its growth initiatives.
More about Acrux Limited
Acrux is a specialty pharmaceutical company known for developing and commercializing topically applied pharmaceutical products. With 25 years of experience, it has successfully marketed products globally, focusing on the United States. The company is engaged in formulating and developing a range of topical generic products, leveraging its skilled workforce and technical expertise to bring affordable products to market. Acrux is open to collaboration and is well-positioned for commercial partnerships and product development opportunities.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.33M
See more insights into ACR stock on TipRanks’ Stock Analysis page.